Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 188

1.

The Phoenix definition of biochemical failure predicts for overall survival in patients with prostate cancer.

Abramowitz MC, Li T, Buyyounouski MK, Ross E, Uzzo RG, Pollack A, Horwitz EM.

Cancer. 2008 Jan 1;112(1):55-60.

2.

Biochemical failure as a determinant of distant metastasis and death in prostate cancer treated with radiotherapy.

Pollack A, Hanlon AL, Movsas B, Hanks GE, Uzzo R, Horwitz EM.

Int J Radiat Oncol Biol Phys. 2003 Sep 1;57(1):19-23.

PMID:
12909210
3.

Defining biochemical failure after radiotherapy with and without androgen deprivation for prostate cancer.

Buyyounouski MK, Hanlon AL, Eisenberg DF, Horwitz EM, Feigenberg SJ, Uzzo RG, Pollack A.

Int J Radiat Oncol Biol Phys. 2005 Dec 1;63(5):1455-62. Epub 2005 Sep 19.

PMID:
16169682
4.

Definitions of biochemical failure that best predict clinical failure in patients with prostate cancer treated with external beam radiation alone: a multi-institutional pooled analysis.

Horwitz EM, Thames HD, Kuban DA, Levy LB, Kupelian PA, Martinez AA, Michalski JM, Pisansky TM, Sandler HM, Shipley WU, Zelefsky MJ, Hanks GE, Zietman AL.

J Urol. 2005 Mar;173(3):797-802.

PMID:
15711272
5.

Unification of a common biochemical failure definition for prostate cancer treated with brachytherapy or external beam radiotherapy with or without androgen deprivation.

Fitch DL, McGrath S, Martinez AA, Vicini FA, Kestin LL.

Int J Radiat Oncol Biol Phys. 2006 Dec 1;66(5):1430-9. Epub 2006 Jun 12.

PMID:
16765527
6.

Practical application of biochemical failure definitions: what to do and when to do it.

Kestin LL, Vicini FA, Martinez AA.

Int J Radiat Oncol Biol Phys. 2002 Jun 1;53(2):304-15.

PMID:
12023134
7.

Comparison of alternative biochemical failure definitions based on clinical outcome in 4839 prostate cancer patients treated by external beam radiotherapy between 1986 and 1995.

Thames H, Kuban D, Levy L, Horwitz EM, Kupelian P, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A.

Int J Radiat Oncol Biol Phys. 2003 Nov 15;57(4):929-43.

PMID:
14575823
8.

Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.

Kupelian P, Thames H, Levy L, Horwitz E, Martinez A, Michalski J, Pisansky T, Sandler H, Shipley W, Zelefsky M, Zietman A, Kuban D.

Int J Radiat Oncol Biol Phys. 2005 Nov 1;63(3):795-9. Epub 2005 May 31.

PMID:
15925452
11.

Intermediate-risk localized prostate cancer in the PSA era: radiotherapeutic alternatives.

Gondi V, Deutsch I, Mansukhani M, O'Toole KM, Shah JN, Schiff PB, Katz AE, Benson MC, Goluboff ET, Ennis RD.

Urology. 2007 Mar;69(3):541-6.

PMID:
17382161
12.

Posttreatment prostate-specific antigen nadir highly predictive of distant failure and death from prostate cancer.

Hanlon AL, Diratzouian H, Hanks GE.

Int J Radiat Oncol Biol Phys. 2002 Jun 1;53(2):297-303.

PMID:
12023133
13.

Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.

Martinez AA, Demanes DJ, Galalae R, Vargas C, Bertermann H, Rodriguez R, Gustafson G, Altieri G, Gonzalez J.

Int J Radiat Oncol Biol Phys. 2005 Aug 1;62(5):1322-31.

PMID:
16029788
16.

Dose-response characteristics of low- and intermediate-risk prostate cancer treated with external beam radiotherapy.

Cheung R, Tucker SL, Lee AK, de Crevoisier R, Dong L, Kamat A, Pisters L, Kuban D.

Int J Radiat Oncol Biol Phys. 2005 Mar 15;61(4):993-1002.

PMID:
15752878
17.

Assessing the impact of an alternative biochemical failure definition on radiation dose response for high-risk prostate cancer treated with external beam radiotherapy.

Cheung R, Tucker SL, Lee AL, Dong L, Kamat A, Pisters L, Kuban DA.

Int J Radiat Oncol Biol Phys. 2005 Jan 1;61(1):14-9.

PMID:
15629589
18.

Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference.

Roach M 3rd, Hanks G, Thames H Jr, Schellhammer P, Shipley WU, Sokol GH, Sandler H.

Int J Radiat Oncol Biol Phys. 2006 Jul 15;65(4):965-74.

PMID:
16798415
19.

Ki-67 staining is a strong predictor of distant metastasis and mortality for men with prostate cancer treated with radiotherapy plus androgen deprivation: Radiation Therapy Oncology Group Trial 92-02.

Pollack A, DeSilvio M, Khor LY, Li R, Al-Saleem TI, Hammond ME, Venkatesan V, Lawton CA, Roach M 3rd, Shipley WU, Hanks GE, Sandler HM.

J Clin Oncol. 2004 Jun 1;22(11):2133-40.

20.

The relationship of increasing radiotherapy dose to reduced distant metastases and mortality in men with prostate cancer.

Jacob R, Hanlon AL, Horwitz EM, Movsas B, Uzzo RG, Pollack A.

Cancer. 2004 Feb 1;100(3):538-43.

Items per page

Supplemental Content

Write to the Help Desk